The circadian clock is an endogenous timekeeping system that regulates ~24-hour rhythms in physiology, behavior, and cellular function. In the brain, the circadian system controls sleep-wake cycles, hormone secretion, metabolic processes, and synaptic plasticity. Emerging evidence demonstrates that circadian dysfunction is both a characteristic feature and a potential contributor to neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). This pathway page explores the molecular architecture of the circadian clock, its disruption in neurodegeneration, and therapeutic targeting strategies.
| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | [1]
|---------|---------------------|---------------------|-----| [2]
| Core Clock Gene Alterations | Reduced BMAL1, PER2, CRY1 expression in AD brain | Altered PER2, CRY1 in substantia nigra | Dysregulated BMAL1, CLOCK in motor neurons | [3]
| Sleep-Wake Rhythm | Severe fragmentation, reduced SWS, increased daytime napping | REM sleep behavior disorder, sleep fragmentation | Sleep disruption, reduced sleep efficiency | [4]
| Melatonin Secretion | Reduced amplitude, phase advances | Severely diminished in PD patients | Altered melatonin rhythms | [5]
| Body Temperature Rhythm | Reduced amplitude, blunted night-time dip | Impaired temperature rhythms | Altered thermoregulation | [6]
| Cortisol Rhythm | Elevated evening cortisol, flattened rhythm | Dysregulated HPA axis | Altered stress response | [7]
| Activity Rhythms | Advanced phase, reduced amplitude, increased night activity | Reduced amplitude, fragmented activity | Decreased daily activity rhythms | [8]
| Molecular Biomarkers | Altered SIRT1, NAMPT, NAD+ rhythms | Decreased NAD+ in dopaminergic neurons | NAD+ metabolism disruption | [9]
| Therapeutic Intervention | Light therapy, melatonin supplementation, zeitgebers | Dopamine agonists, light therapy, exercise | Supportive care, sleep hygiene | [10]
The mammalian circadian clock operates through a transcription-translation feedback loop (TTFL) centered on core clock genes: [11]
Positive Limb: [5:1]
Negative Limb: [6:1]
Auxiliary Components: [7:1]
The CLOCK-BMAL1 complex drives rhythmic expression of hundreds of target genes through E-box motifs in their promoters. These output genes include: [12]
The suprachiasmatic nucleus (SCN) serves as the master pacemaker, synchronizing peripheral clocks in each organ and tissue through neural and humoral signals including cortisol, melatonin, and body temperature rhythms 9. [9:1]
A key finding in AD research is the circadian regulation of amyloid-beta (Aβ) metabolism: [10:1]
Sleep disturbances are among the earliest and most prevalent symptoms in AD: [11:1]
The circadian system influences tau pathology through multiple mechanisms: [13]
Sleep disturbances are extremely common in PD and often precede motor symptoms: [14]
The formation and spread of Lewy bodies exhibits circadian patterns: [15]
Circadian factors influence motor symptom variability in PD: [16]
ALS particularly affects respiratory control systems with circadian dimensions: [17]
Sleep disturbances in ALS have multiple origins: [18]
Emerging evidence links circadian clock genes to ALS pathogenesis: [19]
Bright light exposure is the primary non-pharmacological intervention for circadian disorders: [20]
Melatonin and related compounds offer multiple therapeutic benefits: [21]
Pharmacological targeting of core clock components is an emerging therapeutic strategy: [22]
Non-pharmacological approaches remain foundational: [23]
The circadian clock intersects with several other neurodegenerative mechanisms: [24]
Recent publications highlighting key advances in this mechanism: [25]
Additional evidence sources: [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48]
Mani AK, Parvathi VD, Ravindran S. 'The Anti-Elixir Triad: Non-Synced Circadian Rhythm, Gut Dysbiosis, and Telomeric Damage'. Med Princ Pract. 2025. ↩︎ ↩︎
Hussain Y, Dar MI, Pan X. Circadian Influences on Brain Lipid Metabolism and Neurodegenerative Diseases. Metabolites. 2024. ↩︎ ↩︎
Shamaeizadeh N, Mirian M. 'MicroRNA-219 in the central nervous system: a potential theranostic approach'. Res Pharm Sci. 2024. ↩︎ ↩︎
Mao JQ, Cheng L, Zhang YD. Chinese formula Guben-Jiannao Ye alleviates the dysfunction of circadian and sleep rhythms in APP/PS1 mice implicated in activation of the PI3K/AKT/mTOR signaling pathway. J Ethnopharmacol. 2024. ↩︎ ↩︎
Bachmann et al. Neprilysin activity and expression in AD (2006). 2006. ↩︎ ↩︎
Ju et al. Sleep fragmentation and Aβ deposition in cognitively normal adults (2013). 2013. ↩︎ ↩︎
Nishino et al. Sleep and memory consolidation in AD (2016). 2016. ↩︎ ↩︎
[Di::. Ooms et al., Sleep and Aβ dynamics in Alzheimer's disease (2017). 2017. ↩︎
Zhou et al. SCN pathology in AD (1995). 1995. ↩︎ ↩︎
Yamada et al. Neuronal activity regulates tau release (2018). 2018. ↩︎ ↩︎
Holth et al. Sleep deprivation accelerates tau pathology (2019). 2019. ↩︎ ↩︎
Swaab et al. Circadian rhythm disorders in AD (1994). 1994. ↩︎
Xie et al. Sleep drives metabolite clearance from the brain (2013). 2013. ↩︎
Schenck et al. REM sleep behavior disorder and prodromal neurodegeneration (2013). 2013. ↩︎
Romen-Gershon et al. Excessive daytime sleepiness in PD (2008). 2008. ↩︎
Chahine et al. Sleep in PD (2016). 2016. ↩︎
Fujiwara et al. α-Synuclein phosphorylation rhythms (2017). 2017. ↩︎
Braak et al. Staging of Lewy body pathology (2003). 2003. ↩︎
Duffy et al. Alpha-synuclein and circadian rhythms (2018). 2018. ↩︎
van der Velden et al. Motor fluctuations in PD (2016). 2016. ↩︎
Grace et al. Circadian dopamine metabolism in PD (2009). 2009. ↩︎
Pierangeli et al. Body temperature rhythms in PD (2003). 2003. ↩︎
Fitting et al. Respiratory function in ALS (2006). 2006. ↩︎
Hadjikoutis et al. Bulbar dysfunction in ALS (2005). 2005. ↩︎
Kim et al. Nocturnal hypoventilation in ALS (2014). 2014. ↩︎
Gebru NT, Beaulieu-Abdelahad D, Gulick D. FKBP51 overexpression in the corticolimbic system stabilizes circadian rhythms. Cell Stress Chaperones. 2025. ↩︎
Lo Coco et al. Sleep disturbances in ALS (2016). 2016. ↩︎
David et al. Sleep-disordered breathing in ALS (2008). 2008. ↩︎
Khalil et al. Sleep and psychological aspects in ALS (2013). 2013. ↩︎
Zhang et al. Circadian clock alterations in ALS (2016). 2016. ↩︎
Meguin et al. Clock gene polymorphisms in ALS (2017). 2017. ↩︎
Liu et al. Circadian metabolic dysregulation in ALS (2017). 2017. ↩︎
Dowling et al. Light therapy for circadian disorders in dementia (2008). 2008. ↩︎
Pae et al. Light therapy for sleep and circadian disorders (2015). 2015. ↩︎
Kessel et al. Blue-light effects on circadian rhythms (2012). 2012. ↩︎
Ancoli-Israel et al. Dawn simulation for AD (2003). 2003. ↩︎
Zhang et al. Melatonin therapy for neurodegenerative diseases (2016). 2016. ↩︎
Hatta et al. Ramelteon for sleep disorders in AD (2014). 2014. ↩︎
Cai et al. Agomelatine for cognitive disorders (2014). 2014. ↩︎
Bubenik et al. Melatonin timing in therapeutics (2014). 2014. ↩︎
Solt et al. REV-ERB agonist SR9009 enhances circadian amplitude (2012). 2012. ↩︎
Kojetin et al. ROR modulators for metabolic disease (2015). 2015. ↩︎
Hirano et al. CRY stabilizers as therapeutic agents (2016). 2016. ↩︎
Li et al. CLK inhibitors for circadian disorders (2016). 2016. ↩︎
Walker et al. Sleep hygiene for neurodegenerative disease (2017). 2017. ↩︎
Rovio et al. Exercise timing and circadian rhythms (2015). 2015. ↩︎
Panda et al. Time-restricted feeding and metabolic health (2016). 2016. ↩︎
Ehlert et al. Social zeitgebers and circadian entrainment (2013). 2013. ↩︎